Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Merck
Medtronic
McKesson
Moodys

Last Updated: March 28, 2020

DrugPatentWatch Database Preview

Litigation Details for Senju Pharmaceutical Co. Ltd. v. Apotex Inc. (D. Del. 2007)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Senju Pharmaceutical Co. Ltd. v. Apotex Inc. (D. Del. 2007)

Docket   Start Trial Date Filed 2007-11-29
Court District Court, D. Delaware Date Terminated 2011-12-20
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand None Referred To
Parties ALLERGAN INC.; APOTEX CORP.; APOTEX INC.; APOTEX PHARMACHEM INDIA PVT LTD.; KYORIN PHARMACEUTICAL CO. LTD.; SENJU PHARMACEUTICAL CO. LTD.
Patents 4,551,456; 4,980,470; 5,880,283
Attorneys David B. Abramowitz; Francis J. Murphy , Jr.; Keith D. Parr; Kevin M. Nelson; Maryellen Noreika; Scott B. Feder
Firms Morris, Nichols, Arsht & Tunnell; Murphy, Spadaro & Landon
Link to Docket External link to docket
Small Molecule Drugs cited in Senju Pharmaceutical Co. Ltd. v. Apotex Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Senju Pharmaceutical Co. Ltd. v. Apotex Inc. (D. Del. 2007)

Date Filed Document No. Description Snippet Link To Document
2007-11-29 1 Complaint 4,780,465 10/1988 Ogata et al. ............. 514/254 4,980,470 12/1990 Masuzawa etal. ...... 544/363 5,043,450…expiration of either the ‘045 patent or U.S. Patent 5,880,283 (the ‘283 patent). 26. Apotex Corp. in its…ingcmcnt of United States Letters Patent No. 6,333,045 (‘045 Patent) under 35 U.S.C. §271(€) (2). THE…interest in the ‘045 patent. 19. Allergan is the exclusive licensee of the ‘045 patent for ophthahnic uses…expiration of a listed patent to provide notice to the owner of the listed patent(s) and to the NDA holder External link to document
2010-11-03 129 in view of U.S. Patent Nos. 4,980,470 ("the '470 patent") and 4,551,456 ("the '… the validity of claim 7 of U.S. Patent No. 6,333,045 (the 045 patent). Order Setting Teleconference:(…validity of claim 7 of U.S. Patent No. 6,333,045 (lithe '045 patent"). 1. Background…#39;456 patent"), rendered claim 7 of the '045 patent obvious. (Id. at 37~38) …ophthalmic compositions. ('456 patent at col. 2:5-10) The '470 patent, which discloses the compound External link to document
2008-01-22 13 Answer to Complaint expiration of either the ‘045 patent or U.S. Patent 5 ,880,283 (the ‘283 patent). ANSWER: Apotex admits …enforceability of U.S. Patent Nos. 6,333,045, (“the ‘045 patent”) and 5,880,283 (“the ‘283 patent”). 6. This Court…103, and/or 112. D. Declaring that U.S. Patent No. 5 ,880,283 is invalid for failure to comply with one…infringement of United States Letters Patent No. 6,333,045 (‘045 Patent) under 35 U.S.C. §271(€) (2). ANSWER…expiration of a listed patent to provide notice to the owner of the listed patent(s) and to the NDA holder External link to document
2008-01-22 14 Motion to Dismiss Plaintiffs’ U.S. Patent Nos. 5,880,283 (the “ ‘283 patent”) and 6,333,045 (the “ ‘045 patent”) would not be…the listed patents, namely that: (l) no patent information has been filed, (ll) the patents have expired…Will not market the drug until the patents expire, or (IV) the patents are invalid or Will not be infringed… Counts ll and Ill of Plaintiffs’ Complaint for Patent lnfringement (the “Complaint”) pursuant to Rule…under the Hatch-Waxman Act. BACKGROUND This is a patent infringement case brought under the Hatch-Waxman External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Express Scripts
AstraZeneca
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.